- Clipperton acted as sole financial advisor to Tilak Healthcare on its €10m growth financing led by Cap Horn and Elaia Partners, with the participation of historical investors Swen Capital Partners and iBionext Growth Fund – joined by Laboratoires Théa, the flagship of French ophthalmology – as well as Adelie, and several renowned ophthalmologists and Business Angels, including Yann Fleureau (co-founder of Cardiologs).
- The funds will be used to accelerate the deployment of OdySight in France and internationally and to develop new solutions for other pathologies.
- This transaction illustrates Clipperton’s expertise and rich track record in the digital health space after DentalMonitoring’s $150m growth financing, Inova’s $70m growth investment with Carlyle, or Withings’ $60m round led by Gilde Healthcare, Eurazeo, and Bpifrance.
Our Client
- Tilak Healthcare, founded in 2016 within the iBionext ecosystem, is a company specializing in digital healthcare, particularly in the development of a disruptive technological platform of medical video games prescribed by healthcare professionals to support chronic disease treatments.
- The company has developed OdySight (CE marked Class I medical device), the first solution combining a medical device and a mobile video game for remote monitoring of age-related vision disorders. Since its launch, it has already optimized the care of 12,000 patients suffering from retinal diseases, such as AMD or Diabetic Retinopathy, by enabling its ophthalmologists to monitor in real-time the evolution of their visual acuity in Europe.
- Tilak Healthcare has succeeded in establishing itself within the framework of remote monitoring, which is now covered in France in particular, and in identifying a sustainable business model that will enable it to achieve profitability by 2025.
Deal Rationale
- Tilak Healthcare raises €10m led by Cap Horn and Elaia Partners, with the participation of historical investors – Swen Capital Partners and iBionext Growth Fund – joined by Laboratoires Théa – the flagship of French ophthalmology – Adelie, and several Business Angels and renowned ophthalmologists.
- The arrival of the new shareholder, Théa, Europe’s leading independent ophthalmology laboratory, reinforces the value and importance of OdySight in visual health. It follows on from the collaboration between Tilak Healthcare and Théa in the deployment of OdySight, to open up new opportunities in the care pathway for patients and healthcare professionals.
- According to Edouard Gasser, CEO and co-founder of Tilak Healthcare: “We are very proud to announce this fundraising and to welcome new investors, specialized in digital technologies and healthcare, alongside our long-standing partners who have renewed their confidence in us. They all share our ambition to revolutionize the ophthalmology care pathway with the contribution of digital and video game technologies, helping to improve certain problems facing all healthcare systems worldwide.“
Clipperton’s healthcare track record
- This transaction illustrates Clipperton’s expertise and rich track record in the digital health space after DentalMonitoring’s $150m growth financing, Inova’s $70m growth investment with Carlyle, or Withings’ $60m round led by Gilde Healthcare, Eurazeo, and Bpifrance.
Deal Team
Read the press release in French.
About Clipperton
Clipperton is a leading investment bank dedicated to technology and growth companies. We provide strategic and financial advisory to entrepreneurs, corporates, and top-tier investors in Europe willing to execute transactions such as strategic M&A, private equity transactions, and private placements. Founded in 2003 and with offices in Paris, Berlin, Munich, London, New York, and Beijing, Clipperton has completed over 400 M&A and private placement transactions with fast-growing technology start-ups, blue-chip corporates, and renowned financial investors.